Pfizer to Present More Than 40 Abstracts on Pre-Clinical, Clinical and Outcomes Research at Alzheimer's Association International Conference on Alzheimer's Disease, Pfizer Inc
Release Date: 2010-07-08
NEW YORK, July 8 /PRNewswire-FirstCall/ -- Pfizer Inc. (NYSE: PFE) will present new data on its investigational compounds targeting various aspects of Alzheimer's disease (AD), a complex degenerative brain disorder. New findings on the role of comorbidities, the burden of care and costs associated with AD, also will be discussed. These data, some in collaboration with our partners, will be presented at the Alzheimer's Association International Conference on Alzheimer's Disease 2010 (ICAD 2010) in Honolulu, July 10-15."Biomedical research and development is very risky; for every new medicine that makes it to market, thousands must be screened in discovery. For a complex condition such as Alzheimer's disease, which has multiple factors contributing to its onset and progression, the challenges are even greater," said Steve Romano, vice president, medical affairs head, Pfizer Primary Care Business Unit. "The breadth of data being presented at ICAD 2010 highlights Pfizer's strategic approach to the discovery and development of potential new medicines as it underscores our effort to focus on a range of promising pathological targets. We are committed to advancing the science of AD, with the ultimate goal of delivering innovative and meaningful new treatment options to patients."
| Type: | NORMAL |
| Company: | Pfizer Inc |
| Country: | United States of America |